Why the study?
Does atenolol improve heart rate variability and reduce inflammation in type 1 diabetic patients with depressed HRV?
Does atenolol improve heart rate variability and reduce inflammation in type 1 diabetic patients with depressed HRV?
In type 1 diabetic patients with depressed heart rate variability, beta-blockade with atenolol significantly improves autonomic function and reduces systemic inflammation.
Answers are grounded in this paper and cite their sources.
Atenolol reduces inflammation in T1DM with depressed HRV; extends beta-blocker effects to inflammatory markers in autonomic neuropathy.
AIMS: To assess the relationship between cardiac autonomic dysfunction and inflammation in patients with type 1 diabetes and whether beta-blocker therapy might improve both abnormalities in these patients. METHODS AND RESULTS: We studied 49 patients with type 1 diabetes (age 50.5 +/- 11 years, 33 men). Serum levels of high-sensitivity C-reactive protein, as a marker of inflammation, and frequency-domain heart rate variability (HRV) on 24 h Holter monitoring, as a measure of cardiac autonomic function, were assessed in all patients. Twenty-one patients with depressed HRV were subsequently randomized to receive atenolol (50 mg daily) or no-beta-blockade. HRV and C-reactive protein were re-assessed after 3-4 weeks from randomization. An inverse correlation was found between C-reactive protein levels and HRV parameters, with the highest r coefficient shown with low-frequency (LF) power (r = -0.38; P = 0.007). Furthermore, C-reactive protein serum levels were significantly higher in patients with bottom quartile values of LF power compared with patients with values in the three top quartiles (4.64 +/- 2.8 vs.1.79 +/- 1.6 mg/L, respectively; P = 0.003), also after adjustment for potential confounding variables (P = 0.013). HRV parameters improved significantly in patients treated with atenolol, but not in the no-atenolol group. Furthermore, C-reactive protein levels decreased in the beta-blockade group, but not in the no-beta-blockade group (P = 0.04 for changes between groups). CONCLUSION: In type 1 diabetic patients, serum C-reactive protein levels are significantly associated with depressed HRV; the favourable effects of beta-blockade on both HRV parameters and C-reactive protein serum levels suggest that autonomic nervous system may have significant modulator effects on inflammation.
No takes yet. Share an insight, caveat, or question.
Lanza et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: